Skip to content

Study · Animal study (in vivo) · dog · 2016

8 results

Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure.

Sabbah HN, Gupta RC, Kohli S, Wang M, Hachem S, Zhang K

Circulation. Heart failure1 Feb 2016Cited by 179 (Europe PMC)

PMID26839394 (opens in a new tab)PMCIDPMC4743543 (opens in a new tab)DOI10.1161/circheartfailure.115.002206 (opens in a new tab)PepBankPUB-26839394
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In dogs with microembolization-induced heart failure, 3 months of elamipretide increased ejection fraction versus pretreatment, whereas it decreased in saline controls.

    In plain wordsIn dogs with heart failure, elamipretide raised the heart's ejection fraction after 3 months, while it fell in dogs given saline.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseLeft ventricular ejection fraction
    Study

    dogn = 14

    Microembolization-induced heart failure
    Comparator
    Saline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.5 mg/kg once daily · subcutaneous · 3 monthsAs given in this study (dog).

    Measurements

    Ejection fraction
    36%
    HF+ELA post-treatment
    Ejection fraction
    30%
    HF+ELA pretreatment

    Source sentences

    Summary
    In HF-CON dogs, ejection fraction decreased at post-treatment compared with pretreatment (29 ± 1% versus 31 ± 2%), whereas in HF+ELA dogs, ejection fraction significantly increased at post-treatment compared with pretreatment (36 ± 2% versus 30 ± 2%; P<0.05).
    1 context sentence
    Summary · context
    Fourteen dogs with microembolization-induced HF were randomized to 3 months monotherapy with subcutaneous injections of elamipretide (0.5 mg/kg once daily, HF+ELA, n=7) or saline (control, HF-CON, n=7).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In dogs with heart failure, elamipretide decreased plasma n-terminal pro-brain natriuretic peptide, which increased in saline controls.

    In plain wordsIn dogs with heart failure, elamipretide lowered a blood marker of heart strain, which rose in dogs given saline.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreasePlasma NT-proBNP change
    Study

    dogn = 14

    Microembolization-induced heart failure
    Comparator
    Saline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.5 mg/kg once daily · subcutaneous · 3 monthsAs given in this study (dog).

    Measurements

    NT-proBNP decrease
    774 pg/mL
    HF+ELA

    Source sentences

    Summary
    In HF-CON, n-terminal pro-brain natriuretic peptide increased by 88 ± 120 pg/mL during follow-up but decreased significantly by 774 ± 85 pg/mL in HF+ELA dogs (P<0.001).
    1 context sentence
    Summary · context
    Fourteen dogs with microembolization-induced HF were randomized to 3 months monotherapy with subcutaneous injections of elamipretide (0.5 mg/kg once daily, HF+ELA, n=7) or saline (control, HF-CON, n=7).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In dogs with heart failure, elamipretide normalized plasma tumor necrosis factor-α.

    In plain wordsIn dogs with heart failure, elamipretide brought a blood inflammation marker back to normal.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreasePlasma tumor necrosis factor-α
    Study

    dogn = 14

    Microembolization-induced heart failure
    Comparator
    Saline
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    0.5 mg/kg once daily · subcutaneous · 3 monthsAs given in this study (dog).

    Source sentences

    Summary
    Treatment with elamipretide also normalized plasma tumor necrosis factor-α and C-reactive protein
    1 context sentence
    Summary · context
    Fourteen dogs with microembolization-induced HF were randomized to 3 months monotherapy with subcutaneous injections of elamipretide (0.5 mg/kg once daily, HF+ELA, n=7) or saline (control, HF-CON, n=7).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In dogs with heart failure, elamipretide normalized plasma C-reactive protein.

    In plain wordsIn dogs with heart failure, elamipretide brought a blood inflammation marker back to normal.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreasePlasma C-reactive protein
    Study

    dogn = 14

    Microembolization-induced heart failure
    Comparator
    Saline
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    0.5 mg/kg once daily · subcutaneous · 3 monthsAs given in this study (dog).

    Source sentences

    Summary
    Treatment with elamipretide also normalized plasma tumor necrosis factor-α and C-reactive protein
    1 context sentence
    Summary · context
    Fourteen dogs with microembolization-induced HF were randomized to 3 months monotherapy with subcutaneous injections of elamipretide (0.5 mg/kg once daily, HF+ELA, n=7) or saline (control, HF-CON, n=7).
  5. 05AnimalAnimal study (in vivo)Mechanism

    In cardiomyocytes from dogs with heart failure, elamipretide restored mitochondrial state-3 respiration.

    In plain wordsIn dogs with heart failure, elamipretide restored the energy-making activity of heart cell mitochondria.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMitochondrial state-3 respiration
    Study

    dogn = 14

    Microembolization-induced heart failure
    Comparator
    Saline
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    0.5 mg/kg once daily · subcutaneous · 3 monthsAs given in this study (dog).

    Source sentences

    Summary
    restored mitochondrial state-3 respiration, Δψm, rate of ATP synthesis, and ATP/ADP ratio (ATP/ADP: 0.38 ± 0.04 HF-CON versus 1.16 ± 0.15 HF+ELA; P<0.001).
    2 context sentences
    Summary · context
    Mitochondrial respiration, membrane potential (Δψm), maximum rate of ATP synthesis, and ATP/ADP ratio were measured in isolated LV cardiomyocytes obtained at post-treatment.
    Summary · context
    Fourteen dogs with microembolization-induced HF were randomized to 3 months monotherapy with subcutaneous injections of elamipretide (0.5 mg/kg once daily, HF+ELA, n=7) or saline (control, HF-CON, n=7).
  6. 06AnimalAnimal study (in vivo)Mechanism

    In cardiomyocytes from dogs with heart failure, elamipretide restored mitochondrial membrane potential.

    In plain wordsIn dogs with heart failure, elamipretide restored mitochondrial membrane potential in heart cells.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMitochondrial membrane potential (Δψm)
    Study

    dogn = 14

    Microembolization-induced heart failure
    Comparator
    Saline
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    0.5 mg/kg once daily · subcutaneous · 3 monthsAs given in this study (dog).

    Source sentences

    Summary
    restored mitochondrial state-3 respiration, Δψm, rate of ATP synthesis, and ATP/ADP ratio (ATP/ADP: 0.38 ± 0.04 HF-CON versus 1.16 ± 0.15 HF+ELA; P<0.001).
    2 context sentences
    Summary · context
    Mitochondrial respiration, membrane potential (Δψm), maximum rate of ATP synthesis, and ATP/ADP ratio were measured in isolated LV cardiomyocytes obtained at post-treatment.
    Summary · context
    Fourteen dogs with microembolization-induced HF were randomized to 3 months monotherapy with subcutaneous injections of elamipretide (0.5 mg/kg once daily, HF+ELA, n=7) or saline (control, HF-CON, n=7).
  7. 07AnimalAnimal study (in vivo)Mechanism

    In cardiomyocytes from dogs with heart failure, elamipretide restored the rate of ATP synthesis.

    In plain wordsIn dogs with heart failure, elamipretide restored the rate at which heart cells make ATP, their energy source.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMaximum rate of ATP synthesis
    Study

    dogn = 14

    Microembolization-induced heart failure
    Comparator
    Saline
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    0.5 mg/kg once daily · subcutaneous · 3 monthsAs given in this study (dog).

    Source sentences

    Summary
    restored mitochondrial state-3 respiration, Δψm, rate of ATP synthesis, and ATP/ADP ratio (ATP/ADP: 0.38 ± 0.04 HF-CON versus 1.16 ± 0.15 HF+ELA; P<0.001).
    2 context sentences
    Summary · context
    Mitochondrial respiration, membrane potential (Δψm), maximum rate of ATP synthesis, and ATP/ADP ratio were measured in isolated LV cardiomyocytes obtained at post-treatment.
    Summary · context
    Fourteen dogs with microembolization-induced HF were randomized to 3 months monotherapy with subcutaneous injections of elamipretide (0.5 mg/kg once daily, HF+ELA, n=7) or saline (control, HF-CON, n=7).
  8. 08AnimalAnimal study (in vivo)Mechanism

    In cardiomyocytes from dogs with heart failure, elamipretide restored the ATP/ADP ratio compared with saline controls.

    In plain wordsIn dogs with heart failure, elamipretide restored the ATP/ADP ratio in heart cells, compared with dogs given saline.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseATP/ADP ratio
    Study

    dogn = 14

    Microembolization-induced heart failure
    Comparator
    Saline
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    0.5 mg/kg once daily · subcutaneous · 3 monthsAs given in this study (dog).

    Measurements

    ATP/ADP
    1.16 ratio
    HF+ELA
    ATP/ADP
    0.38 ratio
    HF-CON

    Source sentences

    Summary
    restored mitochondrial state-3 respiration, Δψm, rate of ATP synthesis, and ATP/ADP ratio (ATP/ADP: 0.38 ± 0.04 HF-CON versus 1.16 ± 0.15 HF+ELA; P<0.001).
    2 context sentences
    Summary · context
    Mitochondrial respiration, membrane potential (Δψm), maximum rate of ATP synthesis, and ATP/ADP ratio were measured in isolated LV cardiomyocytes obtained at post-treatment.
    Summary · context
    Fourteen dogs with microembolization-induced HF were randomized to 3 months monotherapy with subcutaneous injections of elamipretide (0.5 mg/kg once daily, HF+ELA, n=7) or saline (control, HF-CON, n=7).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.